QuidelOrtho Corporation (LON: 0A55)
Market Cap | 2.43B |
Revenue (ttm) | 2.10B |
Net Income (ttm) | -1.39B |
Shares Out | n/a |
EPS (ttm) | -20.78 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 265 |
Average Volume | 191 |
Open | 45.22 |
Previous Close | 42.72 |
Day's Range | 43.92 - 45.22 |
52-Week Range | 41.71 - 96.85 |
Beta | n/a |
RSI | 54.33 |
Earnings Date | Feb 12, 2025 |
About QuidelOrtho
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,... [Read more]
News
QuidelOrtho Corp (QDEL) Announces Preliminary Fourth Quarter 2024 Revenue Results
QuidelOrtho Corp (QDEL) Announces Preliminary Fourth Quarter 2024 Revenue Results
QuidelOrtho announces preliminary Q4 2024 revenue in range of $702 million to $707 million
QuidelOrtho expects Q4 2024 revenues to exceed consensus estimates. Non-respiratory revenue projected at $561-563 million.
QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care setting...
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm
NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached ...
QuidelOrtho Corp (QDEL) to Present at 43rd Annual J.P. Morgan Healthcare Conference
QuidelOrtho Corp (QDEL) to Present at 43rd Annual J.P. Morgan Healthcare Conference
QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs ...
QuidelOrtho Announces Appointment of Two Independent Directors to its Board
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care setting...
Vanguard Group Inc's Strategic Acquisition of QuidelOrtho Corp Shares
Vanguard Group Inc's Strategic Acquisition of QuidelOrtho Corp Shares
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
On Tuesday, QuidelOrtho Corporation QDEL priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of 8.26 million shares.
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settin...
QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settin...
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm
NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached...
Top 4 Health Care Stocks That May Plunge This Quarter
As of Nov. 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
QuidelOrtho Corporation (QDEL) Q3 2024 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Juliet Cunningham – Vice President, Investor Relations Brian Blaser – President...
QuidelOrtho Reports Third Quarter 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setting...
QuidelOrtho to Participate in Three Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care setting...
QuidelOrtho to Report Third Quarter 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care setting...
QuidelOrtho Announces New R&D Executive Leader
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Exe...
QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads Quid...
VITROS® Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S.
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its VITROS syphilis assay as part of its ...
QuidelOrtho to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs ...
QUIDELORTHO ALERT: Bragar Eagel & Squire, P.C. is Investigating QuidelOrtho Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against QuidelOrtho Corporation (NASDAQ:...
QuidelOrtho Corporation (QDEL) Q2 2024 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Juliet Cunningham - Vice President-Investor Relations Brian Blaser - President & C...
QuidelOrtho Reports Second Quarter 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care setting...